A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer
Clinical trial NCT00773695 · COMPLETED
Trial details
- NCT number
- NCT00773695
- Sponsor
- Hoffmann-La Roche
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2008-11-07
- Primary completion
- 2022-11-09
- Enrollment
- 150
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.